Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kura Oncology (KURA)

Kura Oncology (KURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 859,226
  • Shares Outstanding, K 88,763
  • Annual Sales, $ 67,480 K
  • Annual Income, $ -278,670 K
  • EBIT $ -304 M
  • EBITDA $ -311 M
  • 60-Month Beta 0.25
  • Price/Sales 11.76
  • Price/Cash Flow N/A
  • Price/Book 4.47

Options Overview Details

View History
  • Implied Volatility 136.65% (+59.86%)
  • Historical Volatility 51.63%
  • IV Percentile 54%
  • IV Rank 21.05%
  • IV High 434.09% on 02/04/26
  • IV Low 57.32% on 08/18/25
  • Expected Move (DTE 24) 0.60 (6.08%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 399
  • Volume Avg (30-Day) 426
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 4,407
  • Open Int (30-Day) 12,437
  • Expected Range 9.19 to 10.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.89
  • Number of Estimates 6
  • High Estimate $-0.76
  • Low Estimate $-1.00
  • Prior Year $-0.66
  • Growth Rate Est. (year over year) -34.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.53 +29.79%
on 03/30/26
10.02 -2.35%
on 04/17/26
+1.52 (+18.40%)
since 03/20/26
3-Month
7.36 +32.93%
on 02/05/26
10.02 -2.35%
on 04/17/26
+1.18 (+13.72%)
since 01/20/26
52-Week
5.45 +79.45%
on 08/11/25
12.49 -21.70%
on 11/14/25
+3.88 (+65.76%)
since 04/17/25

Most Recent Stories

More News
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated...

KURA : 9.78 (+1.03%)
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30...

KURA : 9.78 (+1.03%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)
Kura Oncology: Q4 Earnings Snapshot

Kura Oncology: Q4 Earnings Snapshot

KURA : 9.78 (+1.03%)
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of...

KURA : 9.78 (+1.03%)
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.78 (+1.03%)
Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...

KURA : 9.78 (+1.03%)
1 Under-$10 Stock Set to Surge as Much as 850% in 2026

Kura is a classic high-risk, high-reward biotech investment that has entered a vital growth phase.

KURA : 9.78 (+1.03%)
MRNA : 54.59 (+1.62%)
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

KURA : 9.78 (+1.03%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Key Turning Points

3rd Resistance Point 10.29
2nd Resistance Point 10.07
1st Resistance Point 9.93
Last Price 9.78
1st Support Level 9.57
2nd Support Level 9.35
3rd Support Level 9.21

See More

52-Week High 12.49
Fibonacci 61.8% 9.80
Last Price 9.78
Fibonacci 50% 8.97
Fibonacci 38.2% 8.14
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.